Cargando…
The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective
RAS gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore srl
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462993/ https://www.ncbi.nlm.nih.gov/pubmed/37314870 http://dx.doi.org/10.32074/1591-951X-895 |
_version_ | 1785098154877648896 |
---|---|
author | Malapelle, Umberto Angerilli, Valentina Pepe, Francesco Fontanini, Gabriella Lonardi, Sara Scartozzi, Mario Memeo, Lorenzo Pruneri, Gianfranco Marchetti, Antonio Perrone, Giuseppe Fassan, Matteo |
author_facet | Malapelle, Umberto Angerilli, Valentina Pepe, Francesco Fontanini, Gabriella Lonardi, Sara Scartozzi, Mario Memeo, Lorenzo Pruneri, Gianfranco Marchetti, Antonio Perrone, Giuseppe Fassan, Matteo |
author_sort | Malapelle, Umberto |
collection | PubMed |
description | RAS gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of RAS status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many RAS mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about RAS gene mutational testing in the clinic focusing on the pathologist’s role in patient selection for targeted therapies. |
format | Online Article Text |
id | pubmed-10462993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Pacini Editore srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-104629932023-08-30 The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective Malapelle, Umberto Angerilli, Valentina Pepe, Francesco Fontanini, Gabriella Lonardi, Sara Scartozzi, Mario Memeo, Lorenzo Pruneri, Gianfranco Marchetti, Antonio Perrone, Giuseppe Fassan, Matteo Pathologica Review RAS gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of RAS status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many RAS mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about RAS gene mutational testing in the clinic focusing on the pathologist’s role in patient selection for targeted therapies. Pacini Editore srl 2023-06-14 /pmc/articles/PMC10462993/ /pubmed/37314870 http://dx.doi.org/10.32074/1591-951X-895 Text en © 2023 Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en |
spellingShingle | Review Malapelle, Umberto Angerilli, Valentina Pepe, Francesco Fontanini, Gabriella Lonardi, Sara Scartozzi, Mario Memeo, Lorenzo Pruneri, Gianfranco Marchetti, Antonio Perrone, Giuseppe Fassan, Matteo The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title | The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title_full | The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title_fullStr | The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title_full_unstemmed | The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title_short | The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective |
title_sort | ideal reporting of ras testing in colorectal adenocarcinoma: a pathologists’ perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462993/ https://www.ncbi.nlm.nih.gov/pubmed/37314870 http://dx.doi.org/10.32074/1591-951X-895 |
work_keys_str_mv | AT malapelleumberto theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT angerillivalentina theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT pepefrancesco theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT fontaninigabriella theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT lonardisara theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT scartozzimario theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT memeolorenzo theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT prunerigianfranco theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT marchettiantonio theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT perronegiuseppe theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT fassanmatteo theidealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT malapelleumberto idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT angerillivalentina idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT pepefrancesco idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT fontaninigabriella idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT lonardisara idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT scartozzimario idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT memeolorenzo idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT prunerigianfranco idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT marchettiantonio idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT perronegiuseppe idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective AT fassanmatteo idealreportingofrastestingincolorectaladenocarcinomaapathologistsperspective |